BioMarin's Roctavian gene therapy shows long-term effectiveness in treating severe hemophilia A, reducing bleeding and ...

ATLAS trial investigator Guy Young, MD, Children's Hospital Los Angeles and University of Southern California Keck School of ...

Some patients in England living with severe haemophilia B will soon be able to do away with need for regular infusions, after a weekly, subcutaneous shot from Pfizer was cleared for NHS use. The ...

PDF for Biology from the official Rajasthan Board website. Access chapter-wise details for Biology with the link to download ...

There will soon be two gene therapies available for patients with haemophilia B in the EU after the European Commission approved Pfizer's fidanacogene elaparvovec under the Durveqtix brand name.

CSL Behring has added another major European market to the list of those providing reimbursement coverage of its haemophilia B gene therapy Hemgenix, after agreeing an access deal in Germany. The ...

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...

A rare inherited genetic blood disorder that mostly affects men, hemophilia is on the rise, with more than a million men ...

Roche's Hemlibra treatment for haemophilia A is one of its top-selling drugs, making almost $5 billion last year, and the company has now lined up what looks like an impressive successor. The ...

On World Haemophilia Day, Jens Oltrogge reviews the progress made in treating this rare disorder, which causes those with the disease to bleed because of a lack of sufficient clotting factor ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at the ...